Point72 Hong Kong’s Climb Bio CLYM Stock Holding History

Point72 Hong Kong’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-170	Closed	-$1K	–	2483
2022 Q1	$1K	Buy	+170	New	+$1.59K	﹤0.01%	1761

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parkwood LLC Cleveland, Ohio $1.13B AUM 32.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Point72 Hong Kong's CLYM Position: Q2 2022 in Review

Point72 Hong Kong sold out of Climb Bio (CLYM) in Q2 2022, closing a stake of 170 shares — an estimated $1K sold.

Point72 Hong Kong first reported a position in CLYM in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 29 funds tracked by Wall St. Rank hold CLYM as of Q2 2022.

Point72 Hong Kong reported no remaining Climb Bio position as of Q2 2022 after selling out during the quarter.
Point72 Hong Kong sold 170 Climb Bio shares in Q2 2022, an estimated $1K.
Point72 Hong Kong first reported a position in Climb Bio in Q1 2022 and held it in 1 quarter.
Point72 Hong Kong's Climb Bio position peaked at $1K in Q1 2022.
29 funds tracked by Wall St. Rank held Climb Bio as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.